N14 — The Anticoagulated Patient at the Chair FRONT
Front · at the chair
When: every treatment for a patient on apixaban (Eliquis), warfarin (Coumadin), rivaroxaban (Xarelto), or another blood thinner. The written order and your unit protocol govern.
Do this
- Confirm the drug, the dose, and the last dose every treatment (“Did you take your blood thinner last night and this morning?”). Apixaban dose: per your nephrologist’s order / unit protocol.
- Heparin: per your nephrologist’s order / unit protocol. Don’t assume the standard bolus and infusion apply; if the order doesn’t address the blood thinner, ask before you start.
- If a heparin-free run is ordered, watch for dark streaks in the dialyzer, clot in the venous chamber, or rising venous or transmembrane pressure [3].
- Needle sites: firm pressure without stopping flow (you should still feel the thrill). Time it and write down the minutes every session [12].
- Warfarin: draw the INR with pre-dialysis labs as ordered. Call when the INR is outside the range in the patient’s order [8].
- Ask every week: black or tarry stools, blood in stool or urine, vomiting blood, nosebleeds, new bruising, any fall, any bump to the head [2][9].
- Apixaban on dialysis days: usual times — no hold before treatment, no extra dose after [5][6]. Missed dose: the label says take it as soon as possible that day; never double [7].
- Before a procedure or catheter change: tell the nephrologist the drug and the last dose. Cannulation needs no hold.
- Before the patient leaves: steady, not lightheaded (N5: Intradialytic Hypotension: Chair-Side Response).
Call the nephrologist when
- Now (and follow your unit emergency plan, N12: Chair-Side Emergencies): a fall with a head strike; new headache, confusion, vomiting, weakness, slurred speech, or vision change; vomiting blood; black or bloody stools; bleeding that won’t stop with firm pressure; a fast-growing access hematoma.
- Same day: the INR is outside the range in the patient’s order — now if the patient is bleeding.
- Same day: the circuit clotted on a heparin-free run; blood in the urine; an unexplained hemoglobin drop (N10: Anemia Protocol: ESA and Iron Hold/Report Rules).
- Same day: new aspirin, clopidogrel, prasugrel, ticagrelor, NSAID, “-azole” antifungal, ritonavir, rifampin, carbamazepine, phenytoin, or St. John’s wort [7]; taking both warfarin and apixaban; a dose that doesn’t match the order; the drug stopped or unaffordable.
- At rounds: needle-site bleeding longer than the patient’s usual for three sessions in a row [12]; a fall without a head strike.
- AF patients: see N1: Potassium Bath Selection for potassium call rules.
Don’t
- Don’t give a heparin bolus to a patient on a blood thinner unless it is ordered.
- Don’t stop, skip, hold, or double a dose on your own — or tell the patient to [7].
- Don’t blame all prolonged needle-site bleeding on the drug. Three sessions in a row can mean the access is narrowing (Examining and Cannulating the AVF and AVG).
- Don’t give vitamin K or a reversal drug without an order.
- Don’t let a patient leave after a head strike without talking to the nephrologist.
- Don’t treat a fall as a reason to stop the blood thinner — report it; the physician decides [10].
N14 — The Anticoagulated Patient at the Chair BACK
Back · why, and the evidence
Why
- In RENAL-AF, 26–32% of dialysis patients on apixaban or warfarin had a major or clinically relevant bleed within a year, versus about 3% with a stroke or embolism [1]. GI bleeding is the most common major bleed on dialysis (2.3 per 100 patient-years) [2].
- In a randomized crossover trial, 10 patients on oral anticoagulants had 40 treatments with and without added circuit anticoagulation; none ended early [3]. The UK Kidney Association suggests a heparin-free start (grade 2D) [4]. The trial predates wide apixaban use — so watch the circuit.
- A dialysis session removes about 4% of apixaban, and levels don’t depend on dose timing [5][6]. Dose is debated: the label gives 5 mg twice daily unless age 80 or older or weight 60 kg or less [7]; steady-state data show 2.5 mg twice daily on dialysis matches 5 mg exposure with normal kidneys [5]. Even a 48–72-hour pre-procedure hold may be too short [6].
- In RENAL-AF, warfarin patients were in the target INR range only 44% of the time [1], and in a US dialysis cohort, patients whose INR was not checked in the unit had the highest stroke risk [8]. The UK Kidney Association advises reassessing warfarin when time in range falls below 65% [4].
- Dialysis patients 65 and older fell 1.6 times per person-year; 19% of falls caused injury [9]. Fall risk alone did not change the best stroke-prevention choice [10], but 1-year mortality after a spontaneous subdural hematoma on dialysis was 45.9% — 81% in those previously on an oral anticoagulant [11].
Go deeper
References
- Pokorney SD, et al. Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial (RENAL-AF). Circulation. 2022;146:1735-1745. PubMed 36335914
- Coyle CR, et al. Major bleeding rates in an international cohort of patients with end-stage kidney disease. Kidney Int Rep. 2024;9:2814-2818. PubMed 39291210
- Krummel T, et al. Haemodialysis in patients treated with oral anticoagulant: should we heparinize? Nephrol Dial Transplant. 2014;29:906-913. PubMed 24459138
- UK Kidney Association. Clinical practice guideline: anticoagulation for atrial fibrillation in adults with advanced kidney disease. September 2025. ukkidney.org
- Mavrakanas TA, et al. Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol. 2017;28:2241-2248. PubMed 28302754
- Konecki C, et al. Population pharmacokinetic modelling of apixaban in end-stage kidney disease patients with atrial fibrillation receiving haemodialysis. Clin Pharmacokinet. 2025;64:307-321. PubMed 39853633
- ELIQUIS (apixaban) prescribing information. Bristol-Myers Squibb; DailyMed label, May 2025. dailymed.nlm.nih.gov
- Chan KE, et al. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009;20:2223-2233. PubMed 19713308
- Cook WL, et al. Falls and fall-related injuries in older dialysis patients. Clin J Am Soc Nephrol. 2006;1:1197-1204. PubMed 17699348
- Man-Son-Hing M, et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159:677-685. PubMed 10218746
- Yang L, et al. Nontraumatic subdural hematoma in patients on hemodialysis with end-stage kidney disease: a systematic review and pooled analysis. Front Neurol. 2023;14:1251652. PubMed 37789893
- Lok CE, et al. KDOQI clinical practice guideline for vascular access: 2019 update. Am J Kidney Dis. 2020;75(4 Suppl 2):S1-S164. PubMed 32778223
Reviewed by Andrew Bland, MD, FACP, FAAP · v1.0 draft 2026-09-26. For education; the physician’s written order and the unit protocol always govern.